TPT1P11

Across TCGA pan-cancer cohorts, TPT1P11 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated TPT1P11 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TPT1P11 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TPT1P11 expression acts as an unfavorable survival marker, although some lineages such as GBM and SKCM show a favorable association.

ACC, MESO, and CESC are the cancer types where TPT1P11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Tertile	All	0.113	0.822	<.001	63	view →
MESO	OS	Tertile	III,IV	0.036	0.563	<.001	54	view →
CESC	DFS	Tertile	All	0.422	0.754	<.001	48	view →
THYM	OS	Tertile	II,III,IV	0.169	0.904	.001	45	view →
LIHC	DFS	Tertile	III,IV	0.113	0.369	.004	36	view →
LUSC	DFS	Tertile	II,III,IV	0.198	0.770	<.001	24	view →
GBM	OS	Tertile	All	0.447	0.223	.001	15	view →
SKCM	DFS	Tertile	III,IV	0.812	0.590	.030	9	view →
COAD	OS	Tertile	All	0.813	0.580	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TPT1P11–ACC (OS)

Open the ACC breakdown →